Trial Profile

Phase I dose escalation study of oral administration of S 78454 given as monotherapy in the treatment of patients with refractory or relapsed acute myeloid leukemia, acute lymphoblastic leukemia or high or intermediary-2 risk myelodysplastic syndrome

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 29 Jan 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abexinostat (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions
Sponsors Pharmacyclics; Servier

29 Jan 2018 According to results published in the Leukemia and Lymphoma, the study was closed due to limited clinical benefit.
29 Jan 2018 Status changed from active, no longer recruiting to discontinued, according to results published in the Leukemia and Lymphoma.
17 Dec 2015 Status changed from active, no longer recruiting to completed as per ISRCTN: Current Controlled Trials.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com